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The risk of an osteoporotic hip fracture is greater than the combined risks of breast 
cancer, myocardial infarction and stroke, yet research shows less than 25% of women are 
being screened. Post-menopause, either surgical or natural, is a risk factor for 
osteoporosis. Nurse practitioners are in an excellent position to lead the way in 
osteoporosis screening. This article presents findings in a recent  osteoporosis screening 





Osteoporosis is the leading cause of fractures in persons over 50. 1  Non-hip fractures are 
responsible for 80% of fractures presenting to hospitals worldwide. 2 Only 23% of 
women over age 67 suffering non-hip fragility fractures or hip fractures are evaluated and 
treated for osteoporosis.3 In 2014, prevalence data studied showed 54 million Americans 
50 years and older are affected by osteoporosis, (10 million with osteoporosis) and 
(44million with low bone mass),equaling approximately half of the United States  adult 
population.4  United States Preventative Service Task Force (USPSTF)  estimates by 
2020 12.3 million persons  50 years or older are expected to have osteoporosis.5  
Physiologically fractures occur  as a result of low bone mass. Estimate annual incidence 
of osteoporotic fracture in 2014 is greater than 1.5 million people with a cost estimate of 
more than $17 billion dollars spent yearly on osteoporosis patients.6  Defined by the 
World Health Organization, osteoporosis  is the loss of bone mass and micro-
architectural deterioration of bone which contributes to increased bone fragility leading to 
an increased fracture rate worldwide. 7 Research shows fewer  than 25 % of women are 
being screened.7 This lack in care continues to place women at risk for serious, often 
preventable fractures and their sequelae. Nurse practitioners, as primary care providers 
have an excellent opportunity to be leaders in osteoporosis prevention. 
Literature review by the USPTF in 2017 found that the risk benefit of screening for 
women 65 years and older is at least moderate, and therefore women under the age of 65 
who are post-menopausal, either surgical or natural, with at least one risk factor, should 
also be screened additionally.8 Hadjidakis studied the effects of bone loss in relation to 
the age of menopause and type of menopause, surgical versus natural.9 (Lower vertebral 
bone mineral density was found in women with an early bilateral salpingo-oopherectomy 
(BSO) versus a woman who had a natural menopause in ages 45-55 years old. 10Yoshida 
studied this same cohort measuring the  metabolic biomarker N-terminal 
telopeptide  (NTX ), which is found in the urine with bone turnover.11 He found  there 
existed significant increased NTX  levels from 6 to 12 months following an 
oophorectomy associated with seriously  decreased bone mineral density(BMD) by as 
much as 6.7% at 12 months post -op.  He concluded there is a two-fold increase in lower 
bone density for those women who underwent surgical menopause versus a natural one. 
12  His research illustrates the seriousness of this  problem , which is not given appropriate 
emphasis to providers in the clinical setting . 
Purpose  
The goal of this program was to increase the identification of post-menopausal women 
surgical or natural, between ages 30-64 by screening for those qualified for referral for a 
dual absorptiometry (DXA) test scan  through the use of a nationally recognized and 
accepted screening tool, The Simple Calculated Osteoporosis Risk Estimation (SCORE) 
risk assessment tool. 13.  This program  parallels the level B recommendation by the  
USPSTF which recommends bone density testing in postmenopausal women under the 
age of 65 who have an increased risk of osteoporosis which is determined through the use 
of a formal clinical risk assessment tool. 14The USPSTF evaluated evidence and 
concluded that clinical risk assessment tools including the SCORE assessment tool are 
moderately accurate in identifying those at risk of osteoporosis.15 
All female patients identified as post-menopausal seen in the primary care practice 
between May 2019 and July 2019 were screened with the SCORE tool to determine if 
they were referred for a DXA scan. The DXA scan is done to determine bone density, a 
significant determinate used  in the diagnosis of osteoporosis. 
Identification of Osteoporosis 
According to the 2018 Endocrine society guidelines, DXA scans are considered the gold 
standard utilized in diagnosing osteoporosis.16The evidence states that post-menopausal 
women either surgical or natural have an increased loss of bone mass in the years 
immediately following the decrease in circulating estrogen.17 Currently providers 
collectively have established the practice of providing  bone density testing for women 
over the age of 65, however the evidence clearly states that it is the ocurance of 
menopause with the  depletion of estrogen (occurring either natural or surgically) causing 
the accelerated bone breakdown process leading to osteoporosis  that should be the 
sentinel event precipitating a referral for a DXA scan.18 Evidence supports the process of 
identification of these at risk women needing a DXA scan to evaluate for the presence of 
asymptomatic osteoporosis before the first fracture occurs.19 Research demonstrates that 
the single most significant predictor of osteoporotic risk fracture prediction is  BMD 
which is obtained from a DXA scan. 20 
The Program  
Instructing the medical assistants and providers on accurate completion of the SCORE 
assessment tool was accomplished in our weekly team meeting after approval for the 
program was secured by appropriate administrative chain of command. Each female of 
this select cohort seen in  clinic for 90 consecutive days May 1st through July 1st 2019, 
was screened with the SCORE tool. Upon successful completion of the SCORE screen, 
each female patient identified as at risk by the tool, was referred to have a DXA scan. 
Interpretation of the DXA scan results and formulating the diagnosis of osteoporosis was 
done by a certified clinical densitometrist. Follow up appointments were provided  to 
each individual screened to review results, diagnosis, recommendations and formulate a 
patient centered  treatment plan. This appointment  time was also used to provide  patient 
education of the pathology of osteoporosis as well as pharmaceutical option chosen.  
The Findings 
There were 53 women aged 30-64 surveyed for participation in this program, those 
identified as post-menopausal(either surgical or natural ) were then screened with the 
SCORE  tool. Of the 28 screened ,13 scored high enough to be referred for a DXA scan. 
The result of the scans was consistent with what I have been seeing in practice for the past 
2 years with 13 patients identified with either low bone mass (formerly osteopenia) or 
osteoporosis. This represents 55% of the cohort screened. I anticipated 50% of patients 
surveyed would be identified as at risk for osteoporosis and referred for a DXA scan. This 
significant finding demonstrates that osteoporosis is not just a disease process of elderly 
women but of all post-menopausal women which is occurring in a much earlier time period.  
 
Implications of Practice 
The silent disease of osteoporosis steals independence from women. Exposing this disease 
to the public and providers alike is the first step towards screening patients to identify those 
at highest risk. Numerous metrics are now part of a routine new patient intake assessment. 
Incorporating the short SCORE assessment during this process will  identify those women 
who are post-menopausal needing to be tested by DXA. Just like a mammogram, DXA 
scan evaluation of bone health needs to secure its place in the priority of health testing.  
Educating providers with this information is one of  the critical links to identifying 
potentially affected patients. Early diagnosis and treatment of low bone mass or 
osteoporosis will reverse this condition, and prevent unnecessary fractures.  
Conclusion 
The nurse practitioner is the perfect health care provider to spearhead community education 
programs aimed at teaching the public about this silent disease Empowering people with 
knowledge strengthens their ability to be self-advocates for their health. Share the 
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